<DOC>
	<DOCNO>NCT01998854</DOCNO>
	<brief_summary>Study intend evaluate one-year safety clinical status patient treat symptomatic uterine fibroid VizAblate Intrauterine-ultrasound guide radio frequency ( RF ) ablation system . Particular attention direct record safety outcome include incidence uterine cavity synechiae . In addition , information quality life collect . Overall study duration ( first patient enrol last patient exit ) comprise approximately 12 month patient enrollment 1 month schedule treatment , 12 month follow-up , total duration 25 month . Study duration individual patient , enrol , approximately 1 month baseline observation treatment scheduling , 12 month follow treatment total duration approximately 13 month .</brief_summary>
	<brief_title>Observational Prospective Study Patients With Symptomatic Uterine Fibroids Treated With VizAblate® Intrauterine-ultrasound Guided RF Ablation</brief_title>
	<detailed_description>In single-arm study , subject receive transcervical intrauterine-ultrasound guide RF ablation symptomatic uterine fibroid VizAblate® System assess 3D pelvic sonography contrast , hysteroscopy , quality life questionnaire . Overall study duration ( first patient enrol last patient exit ) comprise approximately 12 month patient enrollment 1 month schedule treatment , 12 month follow-up , total duration 25 month . Study duration individual patient , enrol , approximately 1 month baseline observation treatment scheduling , 12 month follow treatment total duration approximately 13 month .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Fibroma</mesh_term>
	<criteria>28 year age old Indication transcervical treatment uterine fibroid associate menorrhagia Willingness participate study , attend followup visit undergo study assessment , sign inform consent form Presence submucosal and/or intramural fibroid Pregnancy ≥40 year age desire current future fertility , unless estimate risk/benefit ratio determine favorable future pregnancy standard therapy Nonsterilized patient &lt; 40 year age , unless estimate risk/benefit ratio determine favorable future pregnancy standard therapy Active pelvic infection , know suspect gynecologic malignancy premalignant condition Presence tubal implant sterilization Previous pelvic irradiation Endometrial cavity length , include endocervical canal , &lt; 4.5 cm Any abnormality vagina uterine cavity , judgment investigator obstruct access VizAblate handpiece endometrial cavity Presence cardiac pacemaker active implant Postmenopausal</criteria>
	<gender>Female</gender>
	<minimum_age>28 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Menorrhagia</keyword>
	<keyword>Leiomyoma</keyword>
	<keyword>Uterine Fibroids</keyword>
</DOC>